Is Veeva Stock a Buy Now?
Veeva Systems (NYSE: VEEV) is a flashy, high-growth SaaS company disguised as a stuffy old medical compliance company. The company plays a critical role for pharma companies in hastening the time from trial and data collection to selling drugs. At the same time, Veeva's services maintain compliance in a very complex and constantly evolving regulatory environment. Let's take a closer look.
Pharma and Biotech are highly regulated industries. Everything from clinical trials all the way to commercialization and marketing must be documented and approved by the Food and Drug Administration in the U.S. In addition, each state has its own set of regulations to comply with. And that's just the tip of the iceberg. Multinational pharma and biotech companies sometimes must deal with regulations in every country they do business. But wait -- it gets worse. Laws and regulations in each state and country change all the time.
If that sounds like a migraine waiting to happen, it's good news for Veeva. The company's cloud-based solutions help its customers sort through the red tape and allow them to focus on the research and development of drugs and therapies they're in business to create.
Source Fool.com
